S4317

SB 431542 hydrate

Name: SB 431542 hydrate
Brand: SIGMA

≥98% (HPLC), powder, inhibits activation of SMAD proteins

Synonym(s):

4-(5-Benzol[1,3]dioxol-5-yl-4-pyrldin-2-yl-1H-imidazol-2-yl)-benzamide hydrate, 4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide hydrate, 4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide hydrate

Select a Size

All Photos(3)

About This Item

Empirical Formula (Hill Notation):

C₂₂H₁₆N₄O₃ · xH₂O

CAS Number:

301836-41-9

Molecular Weight:

384.39 (anhydrous basis)

UNSPSC Code:

51111800

PubChem Substance ID:

24724609

NACRES:

NA.77

MDL number:

MFCD11045982

Product Name

SB 431542 hydrate, ≥98% (HPLC), powder

SMILES string

O.NC(=O)c1ccc(cc1)-c2nc(-c3ccc4OCOc4c3)c([nH]2)-c5ccccn5

InChI

1S/C22H16N4O3.H2O/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17;/h1-11H,12H2,(H2,23,27)(H,25,26);1H2

InChI key

WQUIJVKNPYBZOF-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

solubility

DMSO: soluble 10 mg/mL
H₂O: insoluble

originator

GlaxoSmithKline

storage temp.

−20°C

Quality Level

100

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Application

SB-431542 was used to study the correlation of platelet-derived growth factor receptor B expression and TGF-β pathway activation in colorectal tumor cells. It was used to study the role of TGF-β signaling in modulation of extracellular matrix and myoblast differentiation.

Biochem/physiol Actions

Potent and selective inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors.

SB-431542 inhibits the TGF-β-mediated activation of SMAD proteins, expression of collagen and fibronectin, cell proliferation and cell motility. It does not inhibit kinases that are activated in response to serum or stress such as ERK, p38 or JNK.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000517761

0000481104

0000477529

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.

N J Laping et al.

Molecular pharmacology, 62(1), 58-64 (2002-06-18)

Transforming growth factor beta1 (TGF-beta1) is a potent fibrotic factor responsible for the synthesis of extracellular matrix. TGF-beta1 acts through the TGF-beta type I and type II receptors to activate intracellular mediators, such as Smad proteins, the p38 mitogen-activated protein

A Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression.

Isogaya K, Koinuma D, Tsutsumi S, et al.

Cell Research, 24(8), 994-1008 (2014)

SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.

Mark D Hjelmeland et al.

Molecular cancer therapeutics, 3(6), 737-745 (2004-06-24)

Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that promotes malignant glioma invasion, angiogenesis, and immunosuppression. Antisense oligonucleotide suppression of TGF-beta(2) ligand expression has shown promise in preclinical and clinical studies but at least two ligands mediate the effects of

The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.

Douglas S Micalizzi et al.

The Journal of clinical investigation, 119(9), 2678-2690 (2009-09-04)

Inappropriate activation of developmental pathways is a well-recognized tumor-promoting mechanism. Here we show that overexpression of the homeoprotein Six1, normally a developmentally restricted transcriptional regulator, increases TGF-beta signaling in human breast cancer cells and induces an epithelial-mesenchymal transition (EMT) that

ALK3-SMAD1/5 Signaling Mediates the BMP2-Induced Decrease in PGE2 Production in Human Endometrial Stromal Cells and Decidual Stromal Cells.

Yu Zhang et al.

Frontiers in cell and developmental biology, 8, 573028-573028 (2020-10-13)

BMP2 is a critical factor that is involved in the processes of embryo implantation and uterine decidualization. The expression of cyclooxygenase (COX) and subsequent prostaglandin E2 (PGE2) production are critical for successful pregnancy. However, it is not clear whether BMP2

View All Related Papers